ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 267 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $537 | +37.0% | 20 | +81.8% | 0.00% | – |
| Q2 2023 | $392 | +40.5% | 11 | 0.0% | 0.00% | – |
| Q1 2023 | $279 | -37.4% | 11 | 0.0% | 0.00% | – |
| Q4 2022 | $446 | – | 11 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 11 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 11 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 11 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 11 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | -50.0% | 11 | -42.1% | 0.00% | – |
| Q2 2021 | $2,000 | +100.0% | 19 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | -50.0% | 19 | -38.7% | 0.00% | – |
| Q4 2020 | $2,000 | +100.0% | 31 | -3.1% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 32 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 32 | +33.3% | 0.00% | – |
| Q1 2020 | $1,000 | -50.0% | 24 | 0.0% | 0.00% | – |
| Q4 2019 | $2,000 | – | 24 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |